Addex Presents Results From GABAB PAM Cough Program At The Thirteenth London International Cough Symposium

Author: Benzinga Newsdesk | July 15, 2024 01:58am

"To our knowledge, this is the first time a highly selective GABAB PAM has demonstrated antitussive activity in animal models of cough," said Dr. Mikhail Kalinichev, Head of Translational Science at Addex, who will be presenting the data. "We believe that a GABAB PAM with antitussive efficacy, combined with reduced centrally-mediated side-effects and improved tolerability in comparison to baclofen, has the potential to become a best-in-class treatment for chronic cough."

Posted In: ADXN